Opus’ LYNX-2 Phase III Trial Hits Primary Endpoint for Post-LASIK Night Vision Treatment
Opus’ phentolamine eye drops hit the LYNX-2 letter-gain target on mesopic low contrast distance visual acuity. Opus Genetics (North Carolina,…
Controversy Meets Creativity: JCRS Experts Challenge Anterior Segment Status Quo at ASCRS
Celebrating surgical innovation and spirited debate at the heart of anterior segment care. The Sunday afternoon JCRS Symposium at ASCRS…
latest posts
